TerminatedPhase 2NCT03627403

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors

Studying Essential thrombocythemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Utah
Principal Investigator
Srinivas Tantravahi, MD
University of Utah
Intervention
Selinexor(drug)
Enrollment
17 enrolled
Eligibility
18 years · All sexes
Timeline
2019 – 2025

Study locations (1)

Collaborators

Karyopharm Therapeutics Inc

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03627403 on ClinicalTrials.gov

Other trials for Essential thrombocythemia

Additional recruiting or active studies for the same condition.

See all trials for Essential thrombocythemia →

← Back to all trials